Next Article in Journal
Barcoding of the Genus Culicoides (Diptera: Ceratopogonidae) in Austria—An Update of the Species Inventory Including the First Records of Three Species in Austria
Previous Article in Journal
A Review: Wolbachia-Based Population Replacement for Mosquito Control Shares Common Points with Genetically Modified Control Approaches
Open AccessReview

Drug Discovery against Acanthamoeba Infections: Present Knowledge and Unmet Needs

1
School of Veterinary Medicine and Science, University of Nottingham, Sutton Bonington LE12 5RD, UK
2
Department of Biology, Chemistry and Environmental Sciences, College of Arts and Sciences, American University of Sharjah, University City, Sharjah 26666, UAE
*
Author to whom correspondence should be addressed.
Pathogens 2020, 9(5), 405; https://doi.org/10.3390/pathogens9050405
Received: 13 April 2020 / Revised: 9 May 2020 / Accepted: 12 May 2020 / Published: 22 May 2020
Although major strides have been made in developing and testing various anti-acanthamoebic drugs, recurrent infections, inadequate treatment outcomes, health complications, and side effects associated with the use of currently available drugs necessitate the development of more effective and safe therapeutic regimens. For any new anti-acanthamoebic drugs to be more effective, they must have either superior potency and safety or at least comparable potency and an improved safety profile compared to the existing drugs. The development of the so-called ‘next-generation’ anti-acanthamoebic agents to address this challenge is an active area of research. Here, we review the current status of anti-acanthamoebic drugs and discuss recent progress in identifying novel pharmacological targets and new approaches, such as drug repurposing, development of small interfering RNA (siRNA)-based therapies and testing natural products and their derivatives. Some of the discussed approaches have the potential to change the therapeutic landscape of Acanthamoeba infections. View Full-Text
Keywords: Acanthamoeba; combination therapy; alternative treatment; drug discovery; natural products; drug repurposing Acanthamoeba; combination therapy; alternative treatment; drug discovery; natural products; drug repurposing
Show Figures

Figure 1

MDPI and ACS Style

Elsheikha, H.M.; Siddiqui, R.; Khan, N.A. Drug Discovery against Acanthamoeba Infections: Present Knowledge and Unmet Needs. Pathogens 2020, 9, 405.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop